Predicted protein targets (top 19)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.69 |
| ▸ | GAA | P10253 | 1/20 | 0.58 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.58 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.58 |
| ▸ | ERN1 | O75460 | 3/20 | 0.56 |
| ▸ | HPGD | P15428 | 1/20 | 0.53 |
| ▸ | ROCK2 | O75116 | 3/20 | 0.52 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.52 |
| ▸ | CYP3A5 | P20815 | 1/20 | 0.52 |
| ▸ | HDAC8 | Q9BY41 | 1/20 | 0.52 |
| ▸ | HDAC6 | Q9UBN7 | 1/20 | 0.52 |
| ▸ | MLYCD | O95822 | 1/20 | 0.52 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.51 |
| ▸ | ATM | Q13315 | 1/20 | 0.51 |
| ▸ | MAOB | P27338 | 1/20 | 0.51 |
| ▸ | ROCK1 | Q13464 | 1/20 | 0.50 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.50 |
| ▸ | LMNA | P02545 | 1/20 | 0.49 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.49 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL13753397 | 0.92 | NPSR1 (0.61) | NPSR1GAAKMT2AHSD17B10ERN1 | |
| SCHEMBL14355565 | 0.92 | NPSR1 (0.61) | NPSR1GAAKMT2AHSD17B10ERN1 | |
| SCHEMBL2977147 | 0.91 | NPSR1 (0.59) | NPSR1GAAKMT2AHSD17B10ERN1 | |
| SCHEMBL958217 | 0.91 | NPSR1 (0.59) | NPSR1GAAKMT2AHSD17B10ERN1 | |
| SCHEMBL165801 | 0.88 | KDM4E (0.61) | NPSR1GAAKMT2AERN1ROCK2 | |
| SCHEMBL165800 | 0.88 | NPSR1 (0.61) | NPSR1GAAKMT2AHSD17B10ERN1 | |
| SCHEMBL30522592 | 0.88 | ATM (0.67) | NPSR1KMT2AHDAC8HDAC6ATM | |
| SCHEMBL1754131 | 0.88 | ATM (0.67) | NPSR1KMT2AHDAC8HDAC6ATM | |
| SCHEMBL13702338 | 0.88 | GAA (0.60) | NPSR1GAAKMT2AHSD17B10ERN1 | |
| SCHEMBL13701782 | 0.88 | NPSR1 (0.60) | NPSR1GAAKMT2AHSD17B10ERN1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 13 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-1998055489-A1 | MULTI-CONSTITUENT SYSTEM FOR MODIFYING, DEGRADING OR BLEACHING LIGNIN, MATERIALS CONTAINING LIGNIN OR SIMILAR SUBSTANCES, AND METHOD FOR USING THE SAME | Consortium für elektrochemische Industrie GmbH (DE) | 1998-12-10 | — | — | WO | claimed |
| US-20230057847-A1 | GLP2 RECEPTOR AGONISTS AND METHODS OF USE | THE SCRIPPS RESEARCH INSTITUTE | 2023-02-23 | — | — | US | disclosed |
| WO-2021113535-A1 | PEPTIDE CONJUGATES AND METHODS OF USE | THE SCRIPPS RESEARCH INSTITUTE (US) | 2021-06-10 | — | — | WO | disclosed |
| WO-2021113524-A2 | GLP2 RECEPTOR AGONISTS AND METHODS OF USE | THE SCRIPPS RESEARCH INSTITUTE (US) | 2021-06-10 | — | — | WO | disclosed |
| US-10940146-B2 | NHE3-binding compounds and methods for inhibiting phosphate transport | ARDELYX, INC. (US) | 2021-03-09 | — | — | US | disclosed |
| US-20190275028-A1 | NHE3-BINDING COMPOUNDS AND METHODS FOR INHIBITING PHOSPHATE TRANSPORT | ARDELYX, INC. (US) | 2019-09-12 | — | — | US | disclosed |
| US-20100221261-A1 | IAP BIR DOMAIN BINDING COMPOUNDS | AEGERA THERAPEUTICS, INC. (CA) | 2010-09-02 | — | — | US | disclosed |
| US-7645741-B2 | Inhibitors of apoptosis proteins (IAP); antiproliferative agents; anticancer agents; bioavailability; coupling; chemical intermediates | AEGERA THERAPEUTICS, INC. | 2010-01-12 | — | — | US | disclosed |
| US-7579320-B2 | IAP BIR domain binding compounds | AEGERA THERAPEUTICS, INC. | 2009-08-25 | — | — | US | disclosed |
| US-20080207525-A1 | Inhibitors of apoptosis proteins (IAP); antiproliferative agents; anticancer agents; bioavailability; coupling; chemical intermediates | PHARMASCIENCE INC. (CA) | 2008-08-28 | — | — | US | disclosed |
| US-20080069812-A1 | Inhibitors of apoptosis proteins (IAP); antiproliferative agents; anticancer agents | AEGERA THERAPEUTICS, INC. (CA) | 2008-03-20 | — | — | US | disclosed |
| WO-2007067836-A2 | SUBSTITUTED PYRAZOLE COMPOUNDS USEFUL AS SOLUBLE EPOXIDE HYDROLASE INHIBITORS | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2007-06-14 | — | — | WO | disclosed |
| WO-1998055489-A1 | MULTI-CONSTITUENT SYSTEM FOR MODIFYING, DEGRADING OR BLEACHING LIGNIN, MATERIALS CONTAINING LIGNIN OR SIMILAR SUBSTANCES, AND METHOD FOR USING THE SAME | Consortium für elektrochemische Industrie GmbH (DE) | 1998-12-10 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100221261-A1 | IAP BIR DOMAIN BINDING COMPOUNDS | BIRC5, BIRC2, BIRC3 | NPSR1 4302/4885GAA 2679/4885KMT2A 4567/4885 |
| US-20190275028-A1 | NHE3-BINDING COMPOUNDS AND METHODS FOR INHIBITING PHOSPHATE TRANSPORT | SLC34A3, SLC34A2, SLC34A1 | NPSR1 1345/4885GAA 796/4885KMT2A 4609/4885 |
| US-20230057847-A1 | GLP2 RECEPTOR AGONISTS AND METHODS OF USE | GLP1R, GIPR, GRPR | NPSR1 119/4885GAA 1693/4885KMT2A 3248/4885 |
| US-20080069812-A1 | Inhibitors of apoptosis proteins (IAP); antiproliferative agents; anticancer agents | BIRC5, XIAP, BIRC2 | NPSR1 4434/4885GAA 1515/4885KMT2A 4399/4885 |
| US-10940146-B2 | NHE3-binding compounds and methods for inhibiting phosphate transport | SLC34A3, SLC34A2, SLC34A1 | NPSR1 1345/4885GAA 796/4885KMT2A 4609/4885 |
| US-20080207525-A1 | Inhibitors of apoptosis proteins (IAP); antiproliferative agents; anticancer agents; bioavailability; coupling; chemical intermediates | BIRC5, XIAP, BAX | NPSR1 4530/4885GAA 1384/4885KMT2A 4542/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.